Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Hélène, Sapin"'
Autor:
Florence Chartier, Louis Soulat, Imane Benabbad, Hélène Sapin, Lyse Bordier, Alexandre Vainchtock, Fanny Raguideau, Roland Cash
Publikováno v:
Diabetes Epidemiology and Management, Vol 7, Iss , Pp 100083- (2022)
Aims: To estimate the number of people with diabetes (PWD) requiring emergency services for severe hypoglycemia (SH) in France and the associated costs. Methods: PWD were identified using the National Health Insurance database (SNDS). Type of diabete
Externí odkaz:
https://doaj.org/article/b2c43962821641f48c8cb2c6413a038c
Autor:
Bruno Guerci, Francesco Giorgino, Hélène Sapin, Kristina Boye, Jérémie Lebrec, Marco Orsini Federici, Elke Heitmann, Anne Dib, Martin Füchtenbusch, Luis‐Emilio García‐Pérez
Publikováno v:
Diabetes, Obesity and Metabolism. 24:2373-2382
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7c8fbdd5e0814484d411df4b85cf94f
https://doi.org/10.1111/dom.14823
https://doi.org/10.1111/dom.14823
Autor:
Karan Vadher, Hiren Patel, Reema Mody, Joshua A. Levine, Meredith Hoog, Alice YY. Cheng, Kevin M. Pantalone, Hélène Sapin
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1861-1868
To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes.The primary analysis was a Bucher aITC of the change from baseline at week 40 in HbA1c (%)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d833f0b51e569728fd160cb254602e5
https://doi.org/10.1111/dom.14775
https://doi.org/10.1111/dom.14775
Autor:
Bruno, Guerci, Francesco, Giorgino, Hélène, Sapin, Kristina, Boye, Jérémie, Lebrec, Marco Orsini, Federici, Elke, Heitmann, Anne, Dib, Martin, Füchtenbusch, Luis-Emilio, García-Pérez
Publikováno v:
Diabetes, obesitymetabolism. 24(12)
The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant treatment change by 24 months in patients with type 2 diabetes (T2D) initiating their first injecta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2ad61c4515541a2e700d5dd3e4d25475
https://pubmed.ncbi.nlm.nih.gov/35876235
https://pubmed.ncbi.nlm.nih.gov/35876235
Autor:
Francesco Giorgino, R. Gentilella, Marco Orsini Federici, Kristina S. Boye, Bruno Guerci, Hélène Sapin, U. Aigner, Luis-Emilio Garcia-Perez, Heike Jung, E. Heitmann, Kirsi Norrbacka, Myriam Rosilio
Publikováno v:
Diabetes Therapy
Introduction The TROPHIES observational study enrolled patients with type 2 diabetes mellitus (T2DM) initiating their first injectable treatment with the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) dulaglutide or liraglutide. This manuscrip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b3086660553c8107e7ebba45cb6e4b
https://doi.org/10.1007/s13300-021-01076-0
https://doi.org/10.1007/s13300-021-01076-0
Autor:
null Bruno Guerci, null Francesco Giorgino, null Hélène Sapin, null Kristina Boye, null Jérémie Lebrec, null Marco Orsini Federici, null Elke Heitmann, null Anne Dib, null Martin Füchtenbusch, null Luis‐Emilio García‐Pérez
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7074bb685d14026d33ff6aae63124b46
https://doi.org/10.1111/dom.14823/v2/response1
https://doi.org/10.1111/dom.14823/v2/response1
Autor:
null Karan Vadher, null Hiren Patel, null Reema Mody, null Joshua A. Levine, null Meredith Hoog, null Alice YY. Cheng, null Kevin M. Pantalone, null Hélène Sapin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fdf8775ff2c37a521091a3a5dc63831
https://doi.org/10.1111/dom.14775/v2/response1
https://doi.org/10.1111/dom.14775/v2/response1
Publikováno v:
The European Journal of Health Economics
Background Health economic evaluations require cost data as key inputs. Many countries do not have standardized reference costs so costs used often vary between studies, thereby reducing transparency and transferability. The present review provided a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc24ee3b546aac5bd1ee990b6b53b0ab
http://europepmc.org/articles/PMC7561572
http://europepmc.org/articles/PMC7561572
Autor:
Hélène Sapin, Marco Orsini Federici, E. Heitmann, U. Aigner, Luis-Emilio Garcia-Perez, Myriam Rosilio, Kristina S. Boye, Kirsi Norrbacka, Francesco Giorgino, Heike Jung, Bruno Guerci
Publikováno v:
Diabetes Therapy
Introduction Although patient-reported outcome (PRO) measures provide important information beyond clinical data, studies that assess the PROs of type 2 diabetes mellitus (T2DM) patients initiating injectable glucose-lowering medications in routine c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b930fdac218b2bfe4e1a448e004f0aad
https://doi.org/10.1007/s13300-020-00908-9
https://doi.org/10.1007/s13300-020-00908-9